The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes
Open accessAbstract
Stratifying the management of type 2 diabetes (T2D) has to take into account marked variability in patient phenotype due to heterogeneity in its pathophysiology, different stages of the disease process, and multiple other patient factors including comorbidities. The focus here is on the very challenging subgroup of patients with T2D who are overweight or obese with insulin resistance (IR) and the most refractory hyperglycemia due to an inability to change lifestyle to reverse positive energy balance. For this subgroup of patients with T2D, we question the dogma that IR is primarily harmful to the body and should be counteracted at any cost. Instead we propose that IR, particularly in this high-risk subgroup, is a defense mechanism that protects critical tissues of the cardiovascular system from nutrient-induced injury. Overriding IR in an effort to lower plasma glucose levels, particularly with intensive insulin therapy, could therefore be harmful. Treatments that nutrient off-load to lower glucose are more likely to be beneficial. The concepts of “IR as an adaptive defense mechanism” and “insulin-induced metabolic stress” may provide explanation for some of the unexpected outcomes of recent major clinical trials in T2D. Potential molecular mechanisms underlying these concepts; their clinical implications for stratification of T2D management, particularly in overweight and obese patients with difficult glycemic control; and future research requirements are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Randle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093 · cited 2×
“The myocardium, with its high-energy needs, adapts to the predominant nutrient source through complex interactions between glucose and FFA metabolism (12,13).”
BackgroundGlucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Self-citationInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Cited by
Insulin action and resistance in obesity and type 2 diabetes
Czech, M. P. (2017) · Nature Medicine · doi:10.1038/nm.4350 · Cited by 1,258
Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes
Shah, M. S., & Brownlee, M. (2016) · Circulation Research · doi:10.1161/circresaha.116.306923 · Cited by 602
Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans
Stefan, N., Schick, F., & Häring, H.-U. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.008 · Cited by 575
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Di Pino, A., & DeFronzo, R. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00141 · Cited by 535
Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective
Zaccardi, F., Webb, D. R., Yates, T., & Davies, M. J. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2015-133281 · Cited by 561
Lipid Use and Misuse by the Heart
Schulze, P. C., Drosatos, K., & Goldberg, I. J. (2016) · Circulation Research · doi:10.1161/circresaha.116.306842 · Cited by 352
Yun, J.-S., & Ko, S.-H. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154838 · Cited by 292
Janssen, J. A. M. J. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157797 · Cited by 294
Nolan, C. J., & Prentki, M. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164119827611 · Cited by 292
Self-citationCardiac lipid metabolism, mitochondrial function, and heart failure
Da Dalt, L., Cabodevilla, A. G., Goldberg, I. J., & Norata, G. D. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad100 · Cited by 258
Ectopic and Visceral Fat Deposition in Lean and Obese Patients With Type 2 Diabetes
Levelt, E., Pavlides, M., Banerjee, R., Mahmod, M., Kelly, C., Sellwood, J., Ariga, R., Thomas, S., Francis, J., Rodgers, C., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.597 · Cited by 222
Ren, B., Chen, C., Li, C., Fu, X., You, L., & Liu, R. H. (2017) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2017.05.094 · Cited by 217
Papakonstantinou, E., Oikonomou, C., Nychas, G., & Dimitriadis, G. D. (2022) · Nutrients · doi:10.3390/nu14040823 · Cited by 199
“This way of life triggers mechanisms, such as development of insulin resistance (IR), proposed as a defense system against metabolic stress, especially for the heart [2].”
BackgroundHaghighatpanah, M., Nejad, A. S. M., Haghighatpanah, M., Thunga, G., & Mallayasamy, S. (2018) · Osong Public Health and Research Perspectives · doi:10.24171/j.phrp.2018.9.4.05 · Cited by 186
A causal role for hyperinsulinemia in obesity
Templeman, N. M., Skovsø, S., Page, M. M., Lim, G. E., & Johnson, J. D. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0449 · Cited by 168
Chen, T., Zhang, Y., Liu, Y., Zhu, D., Yu, J., Li, G., Sun, Z., Wang, W., Jiang, H., & Hong, Z. (2019) · Aging · doi:10.18632/aging.102263 · Cited by 134
Mild suppression of hyperinsulinemia to treat obesity and insulin resistance
Page, M. M., & Johnson, J. D. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.03.018 · Cited by 99
Oellgaard, J., Gæde, P., Rossing, P., Rørth, R., Køber, L., Parving, H.-H., & Pedersen, O. (2018) · Diabetologia · doi:10.1007/s00125-018-4642-y · Cited by 86
Self-citationInsulin Metabolism in Polycystic Ovary Syndrome: Secretion, Signaling, and Clearance
Herman, R., Sikonja, J., Jensterle, M., Janez, A., & Dolzan, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043140 · Cited by 69
“Thus, the frequently observed IR in the pathogenesis of metabolic diseases could be seen as a protective cell mechanism against glucolipotoxicity in the state of constant positive energy balance by limiting the entry of excess glucose in the cells at times of concomitant high free fatty acid availability [25].”
BackgroundInfluentialPioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes
Clarke, G. D., Solis-Herrera, C., Molina-Wilkins, M., Martinez, S., Merovci, A., Cersosimo, E., Chilton, R. J., Iozzo, P., Gastaldelli, A., Abdul-Ghani, M., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0078 · Cited by 63
Gentreau, M., Chuy, V., Féart, C., Samieri, C., Ritchie, K., Raymond, M., Berticat, C., & Artero, S. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12114 · Cited by 50
Insulin resistance and metabolic flexibility as drivers of liver and cardiac disease in T2DM
Colosimo, S., Mitra, S. K., Chaudhury, T., & Marchesini, G. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111016 · Cited by 38
El Massry, M., Alaeddine, L. M., Ali, L., Saad, C., & Eid, A. A. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200908114902 · Cited by 27
Class IIa HDACs inhibit cell death pathways and protect muscle integrity in response to lipotoxicity
Martin, S. D., Connor, T., Sanigorski, A., McEwen, K. A., Henstridge, D. C., Nijagal, B., De Souza, D., Tull, D. L., Meikle, P. J., Kowalski, G. M., et al. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06319-5 · Cited by 16
Metadata
- Authors
- Nolan, C. J., Ruderman, N. B., Kahn, S. E., Pedersen, O., & Prentki, M.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2015-02-17
- Volume
- 64
- Issue
- 3
- Pages
- 673-686
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2171843668
- Cited by
- 226
- References
- 29
- FWCI
- 21.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.